生物
坏死性下垂
自噬
裂谷1
细胞生物学
细胞凋亡
促炎细胞因子
癌症研究
炎症
程序性细胞死亡
免疫学
生物化学
作者
Diego Rojas‐Rivera,Sebastián Beltrán,Francisco Muñoz-Carvajal,Pablo Ahumada-Montalva,Lorena Abarzúa,Laura Gómez,Fernanda Hernández,Cristian A Bergmann,Luis Labrador,Melissa Nassif,Mathieu J.M. Bertrand,Patrício Manque,Ute Woehlbier
出处
期刊:Autophagy
[Taylor & Francis]
日期:2024-06-14
卷期号:: 1-16
被引量:2
标识
DOI:10.1080/15548627.2024.2367923
摘要
Mesenchymal stem cells (MSCs) are used in cell therapy; nonetheless, their application is limited by their poor survival after transplantation in a proinflammatory microenvironment. Macroautophagy/autophagy activation in MSCs constitutes a stress adaptation pathway, promoting cellular homeostasis. Our proteomics data indicate that RUBCNL/PACER (RUN and cysteine rich domain containing beclin 1 interacting protein like), a positive regulator of autophagy, is also involved in cell death. Hence, we screened MSC survival upon various cell death stimuli under loss or gain of function of RUBCNL. MSCs were protected from TNF (tumor necrosis factor)-induced regulated cell death when RUBCNL was expressed. TNF promotes inflammation by inducing RIPK1 kinase-dependent apoptosis or necroptosis. We determine that MSCs succumb to RIPK1 kinase-dependent apoptosis upon TNF sensing and necroptosis when caspases are inactivated. We show that RUBCNL is a negative regulator of both RIPK1-dependent apoptosis and necroptosis. Furthermore, RUBCNL mutants that lose the ability to regulate autophagy, retain their function in negatively regulating cell death. We also found that RUBCNL forms a complex with RIPK1, which disassembles in response to TNF. In line with this finding, RUBCNL expression limits assembly of RIPK1-TNFRSF1A/TNFR1 complex I, suggesting that complex formation between RUBCNL and RIPK1 represses TNF signaling. These results provide new insights into the crosstalk between the RIPK1-mediated cell death and autophagy machineries and suggest that RUBCNL, due to its functional duality in autophagy and apoptosis/necroptosis, could be targeted to improve the therapeutic efficacy of MSCs.
科研通智能强力驱动
Strongly Powered by AbleSci AI